What Is Liver Elastography? The Complete Clinical Guide
Liver elastography is a non-invasive way to estimate fibrosis and steatosis without relying on biopsy as the first answer. For Australian clinicians, it sits at the centre of the current shift toward earlier liver risk stratification in MAFLD, viral hepatitis, and chronic liver disease.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes. This content does not replace clinician judgement or individual medical advice.
What liver elastography actually measures
Elastography estimates tissue stiffness by generating a mechanical or acoustic wave and calculating how quickly that wave moves through the liver. Stiffer tissue usually reflects greater fibrosis, while attenuation-based outputs can help estimate steatosis.
In practice, clinicians use liver elastography to complement history, blood tests, and imaging. It is especially useful because it can be repeated over time, making it valuable for monitoring rather than just one-off diagnosis.
- LSM in kPa estimates liver stiffness and fibrosis burden.
- CAP or UAP helps quantify steatosis and fatty liver burden.
- A larger measurement volume reduces the sampling error seen with biopsy.
How it works in the clinic
The scan is designed to be quick and point-of-care friendly. A probe delivers a pulse, the device measures shear wave propagation, and the system calculates a stiffness value that can be interpreted against aetiology-specific cut-offs.
The Australian opportunity is not just the technology itself, but where it can be deployed. The market research points to growing demand in GP clinics, imaging centres, and community-based metabolic care where access is currently limited.
Clinical uses and who performs it
Liver elastography is most commonly used in MAFLD, hepatitis B, hepatitis C, and cirrhosis surveillance, but its practical role is expanding wherever sequential, non-invasive monitoring is needed.
Depending on the setting, scans may be performed by a GP, nurse, gastroenterologist, sonographer, or radiology team. The simpler the workflow, the easier it becomes to move fibrosis assessment away from tertiary bottlenecks.
- Primary care: second-line testing after indeterminate FIB-4 results.
- Specialist care: fibrosis staging, treatment monitoring, and triage.
- Imaging centres: a complementary service to abdominal ultrasound.
Why guided versus blind matters
One of the biggest differences between systems is whether the operator can see where they are measuring. Blind VCTE relies on external landmarks or simple pulse guidance, while guided systems allow the clinician to visualise liver parenchyma in real time.
That difference matters most in obese patients and technically difficult scans, which is why the playbook places the guided-versus-blind narrative at the centre of the Australian strategy.